The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes
1:34:26CME Available: https://auau.auanet.org/node/33881 At the conclusion of this course, participants will be able to: 1. Describe the various 3rd line therapies available to treat refractory OAB and will be able to discuss the pros and cons of each of the 3rd line therapies available to treat refractory OAB. 2. Explain with the current data regarding outcomes of PTNS, onabotulinumtoxinA, and sacral neuromodulation for treatment of refractory OAB. 3. Outline how to perform PTNS. Report how to perform onabotunlinumtoxinA injections in the office or outpatient setting. 5. Review techniques in optimal lead placement for sacral neuromodulation, programming and troubleshooting. ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AbbVie Medtronic Urovant Sciences, Inc.
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer
1:46:56CME Available: https://auau.auanet.org/node/33900 At the conclusion of this course, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC 2. Describe sequencing and indications for active treatment with approved agents in the management of nmCRPC 3. Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines 4. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice 5. Analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer ACKNOWLEDGEMENTS Independent educational grant support provided by: Amgen Astellas AstraZeneca Bristol-Myers Squibb Exact Sciences Corporation Janssen Biotech, Inc. Administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. Sanofi Genzyme
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma
1:36:45Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment CME Available: https://auau.auanet.org/node/33917 At the conclusion of this course, participants will be able to: 1. Manage bleeding complications of robotic partial nephrectomy 2. Describe the algorithm of Immunotherapy treatment of advanced Renal Cell Carcinoma 3. Minimize positive margin rates of robotic partial nephrectomy ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Bristol-Myers Squibb Merck
Management Of Non Muscle Invasive Bladder Cancer: Practical Solutions For Common Problems
1:34:25CME Available: https://auau.auanet.org/node/33910 At the conclusion of this course, participants will be able to: 1. Implement current practice guidelines into the office setting. 2. Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Bristol-Myers Squibb Merck
Understanding Intrarenal Pressure
30:10This podcast was funded by and developed in collaboration with Boston Scientific
Live from AUA2021: Highlights in Overactive Bladder (2021)
58:41CME Available: https://auau.auanet.org/node/33094 Acknowledgements This educational activity is supported by an independent educational grant from: Urovant
Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)
1:00:51CME Available: https://auau.auanet.org/node/33093 At the conclusion of the activity, participants will be able to: 1. Describe recent developments in the medical management of advanced prostate cancer. 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Discuss clinical investigations in the treatment of advanced prostate cancer. 4. Analyze the risks and benefits of treatment for advanced prostate cancer. 5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer. Acknowledgements This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.
32:21NMIBC Guidelines by AUAUniversity
Improving Racial Disparities in Treatment Outcomes Podcast
37:24Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc. CME Available: auau.auanet.org/node/31819 At the conclusion of this educational series, participants will be able to: 1. Recognize Urologic disparities within the context of disparities in health overall. 2. Summarize the effect of the Affordable Care Act on access to care, and discuss strategies to implement further. 3. Describe how Urologic workforce diversification can improve health outcomes.
Urolithiasis: Metabolic Evaluation and Medical Management
1:39:17Urolithiasis: Metabolic Evaluation and Medical Management by AUAUniversity